{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-23-000031","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.549550+00:00","generated_at":"2026-06-15T08:35:10.761440+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Supernus Q1 revenue flat at $153.8M; Qelbree sales triple to $25.8M; raises FY 2023 guidance","bullets":["Q1 total revenues $153.8M (+1% YoY); GAAP operating earnings $5.2M vs $2.0M; net earnings $16.9M ($0.29/sh) vs $25.6M ($0.43/sh).","Qelbree net sales $25.8M (vs $8.3M YoY); GOCOVRI $26.0M (+15%); Trokendi XR fell 45% to $34.8M due to generic entry.","Excluding Trokendi XR, net product sales up 25% YoY; total IQVIA Qelbree prescriptions rose 14% QoQ to 134,530.","Raising FY 2023 GAAP operating loss guidance to $(30)-$(10)M from $(40)-$(10)M; non-GAAP operating earnings raised to $75-100M.","Repaid $402.5M of 0.625% convertible notes due 2023 on April 1; credit line balance of $78.4M to be fully repaid by Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-23-000031","json":"https://secwatch.observer/filing/0001356576-23-000031.json","markdown":"https://secwatch.observer/filing/0001356576-23-000031.md","text":"https://secwatch.observer/filing/0001356576-23-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000031/0001356576-23-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000031/supn-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:35:10.761440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c61f402cac837409fdcc9d7bc355d1b3b58287df","claim":"SUPERNUS PHARMACEUTICALS, INC. reported First Quarter 2023 results: revenue 153.8 million, net income 16.9 million, EPS 0.29. Guidance raised.","evidence_excerpt":"Supernus Announces First Quarter 2023 Financial Results • First quarter 2023 total revenues of $153.8 million, compared to $152.5 million in first quarter 2022 – Qelbree ® net product sales of $25.8 million, compared to $8.3 million in first quarter 2022 – GOCOVRI ® net product sales of $26.0 million, compared to $22.6 million in first quarter 2022 – Excluding net product sales of Trokendi XR ® in both periods, total net product sales increased 25% • First quarter 2023 GAAP operating earnings of $5.2 million, compared to $2.0 million in first quarter 2022 • First quarter 2023 non-GAAP operating earnings of $30.5 million, compared to $28.0 million in first quarter 2022 • Raises full year 2023 GAAP and non-GAAP operating earnings guidance ROCKVILLE, MD, May 9, 2023 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000031/0001356576-23-000031-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"First Quarter 2023"},{"label":"Revenue","value":"153.8 million"},{"label":"Net income","value":"16.9 million"},{"label":"EPS","value":"0.29"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}